Oral Autoimmune Drug Enters Development Via $1.1B Deal
The experimental VAV1-targeting pill is still in research, with a mid-stage rheumatoid arthritis trial planned for 2027.
Updated on Nov. 4, 2026 in Biotech
Evommune has licensed rights to EVO570, an experimental oral drug for autoimmune diseases, from Hinova Pharmaceuticals, in a deal worth up to $1.1 billion. The rights cover all territories outside Greater China. The drug is in development, not approved, so the deal is a research-stage asset.
Why it matters
The deal extends Evommune's pipeline of treatments for chronic inflammatory diseases and gives it a foothold in research on VAV1, a signaling protein targeted by EVO570. It reflects a trend of Western drugmakers licensing early-stage assets from Chinese developers to fill their pipelines.
The disclosed figures are deal economics rather than performance data: a $30 million upfront payment and up to $1.1 billion in milestones and royalties. The extraction includes no measured efficacy, safety or potency result for EVO570, so the deal's value rests on the drug's unproven clinical profile.
The players
Evommune
A California-based drug developer focused on chronic inflammatory and immune diseases, now expanding its pipeline with an oral VAV1-targeting candidate.
Hinova Pharmaceuticals
A Chengdu-based drugmaker developing treatments for cancer, autoimmune and metabolic diseases, and marketing a prostate cancer therapy in China.
The details
EVO570 is an experimental oral drug designed to treat autoimmune diseases, where the immune system attacks the body's own tissue, by targeting VAV1. VAV1 is a signaling protein, a molecular relay inside immune cells that passes activation messages onward, and blocking it is intended to dampen the inflammatory response. Under the agreement, Evommune gains rights outside Greater China to develop, manufacture and commercialize the drug, while Hinova keeps the Chinese market and receives payments tied to progress.
Timeline
Evommune plans to start a mid-stage study of EVO570 in rheumatoid arthritis in 2027.
The Tech Race
The deal places EVO570 among experimental oral therapies aimed at immune signaling targets in autoimmune disease, where companies are competing to find alternatives to injected biologics. Its VAV1 mechanism gives Evommune a differentiated position in a field crowded with other intracellular pathway candidates.
The drug is not available to patients and remains in research, with no approval or pricing announced. Patients with autoimmune conditions would see any effect only after clinical trials conclude, a process that has not yet reached the mid-stage study planned for 2027.
The takeaway
Watch for the start of Evommune's mid-stage rheumatoid arthritis study of EVO570 in 2027, which will be the first public test of whether the VAV1 approach works in patients. Clinical data from that trial will confirm or reject the deal's premise.
What happens next
Evommune plans to start a mid-stage study of EVO570 in rheumatoid arthritis in 2027, the next concrete milestone for the asset.
Further reading
For more on how drugmakers are tapping early-stage research, explore our Biotech coverage.
